Detalhe da pesquisa
1.
Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes.
Cell
; 166(3): 596-608, 2016 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27453466
2.
Potently neutralizing and protective human antibodies against SARS-CoV-2.
Nature
; 584(7821): 443-449, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32668443
3.
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.
N Engl J Med
; 385(15): 1382-1392, 2021 10 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34260849
4.
Influenza hemagglutinin membrane anchor.
Proc Natl Acad Sci U S A
; 115(40): 10112-10117, 2018 10 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30224494
5.
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
JAMA
; 325(7): 632-644, 2021 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33475701
6.
Rapid development of broadly influenza neutralizing antibodies through redundant mutations.
Nature
; 516(7531): 418-22, 2014 Dec 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-25296253
7.
Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza.
Antimicrob Agents Chemother
; 62(11)2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30150460
8.
The Hemagglutinin A Stem Antibody MEDI8852 Prevents and Controls Disease and Limits Transmission of Pandemic Influenza Viruses.
J Infect Dis
; 216(3): 356-365, 2017 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28633457
9.
A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head.
J Virol
; 88(12): 6743-50, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24696468
10.
Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 Trial.
Infect Dis Ther
; 12(7): 1861-1873, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37329415
11.
Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies.
MAbs
; 15(1): 2152526, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36476037
12.
The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination.
Sci Transl Med
; 14(655): eabn3041, 2022 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35679357
13.
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans.
Sci Transl Med
; 14(635): eabl8124, 2022 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35076282
14.
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.
bioRxiv
; 2022 Mar 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33972947
15.
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.
Cell Rep
; 39(7): 110812, 2022 05 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35568025
16.
Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
Front Immunol
; 12: 790469, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34956222
17.
Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals.
bioRxiv
; 2020 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-32511409
18.
Survival during influenza-associated bacterial superinfection improves following viral- and bacterial-specific monoclonal antibody treatment.
JCI Insight
; 4(14)2019 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-31341107
19.
Tackling influenza with broadly neutralizing antibodies.
Curr Opin Virol
; 24: 60-69, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28527859
20.
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.
Sci Transl Med
; 9(388)2017 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28469033